By Fineline Cube 
CureVac N.V. (NASDAQ: CVAC) announced on August 7, 2025, that it has reached an agreement with GlaxoSmithKline plc (GSK, NYSE: GSK) to resolve and dismiss all pending patent litigation in the United States related to mRNA-based COVID-19 vaccines. The settlement also involves BioNTech SE (NASDAQ: BNTX) and Pfizer Inc. (NYSE: PFE), and establishes a framework for addressing ongoing patent disputes outside the U.S. following the closing of BioNTech’s acquisition of CureVac, announced on June 12, 2025.
Financial Terms
Under the terms of the agreement, CureVac and GSK will collectively receive a payment of $740 million. Additionally, they will earn single-digit royalties on future sales of COVID-19 vaccines in the United States. CureVac will also receive $50 million from GSK for monetizing a portion of the U.S. product royalties it is owed under an existing licensing agreement announced on July 3, 2024.
License Agreement
As part of the settlement, CureVac will grant BioNTech and Pfizer a non-exclusive license to manufacture, use, import, and sell mRNA-based COVID-19 and/or influenza products within the U.S. This license will expand to a worldwide scope upon the closing of BioNTech’s acquisition of CureVac. The acquisition, announced on June 12, 2025, remains subject to regulatory approval and is proceeding as planned.-Fineline Info & Tech